OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) saw unusually-high trading volume on Thursday . 309,963 shares changed hands during trading, an increase of 80% from the previous session’s volume of 171,784 shares.The stock last traded at $22.0010 and had previously closed at $21.68.
Key Headlines Impacting OrthoPediatrics
Here are the key news stories impacting OrthoPediatrics this week:
- Positive Sentiment: OrthoPediatrics crossed the $70 million revenue level and reportedly increased its guidance, signaling continued demand for its pediatric orthopedic products and potentially stronger future growth. OrthoPediatrics Crosses $70M as Guidance Climbs Higher
- Positive Sentiment: Analyst sentiment remains favorable: nine analysts rate the stock Buy, one rates it Hold and one rates it Sell. The consensus rating is Moderate Buy with an average price target of $26.44; BTIG and Needham recently raised their targets to $29 and $35, respectively.
- Positive Sentiment: Institutional ownership is substantial at approximately 69%, while several investment firms—including Millennium Management, BlackRock, Granahan Investment Management and Wasatch Advisors—have recently increased or initiated positions.
- Neutral Sentiment: Reported short interest was zero shares as of September 10, leaving no meaningful short-covering catalyst or bearish short-position overhang.
- Negative Sentiment: Director David Pelizzon, also identified in related filings as major shareholder entities associated with Jennifer Pritzker and Squadron Capital, sold 302,369 shares at an average price of $21.01 for approximately $6.35 million. The sale reduced the reported holding by 4.65%, which may pressure sentiment, although the insider still retained about 6.2 million shares. SEC Insider Sale Filing
Wall Street Analyst Weigh In
A number of research analysts have issued reports on KIDS shares. BTIG Research upped their price objective on OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Needham & Company LLC raised their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.44.
OrthoPediatrics Trading Up 2.3%
The firm has a 50 day moving average of $22.01 and a 200 day moving average of $19.04. The firm has a market cap of $575.99 million, a PE ratio of -13.13 and a beta of 0.99. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Equities analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.
Insider Buying and Selling
In related news, major shareholder Jennifer Pritzker sold 302,369 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the sale, the insider directly owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. The trade was a 4.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David Pelizzon sold 302,369 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the director directly owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 2,100,000 shares of company stock valued at $46,747,931. 32.50% of the stock is owned by insiders.
Institutional Trading of OrthoPediatrics
A number of institutional investors have recently modified their holdings of KIDS. Squarepoint Ops LLC boosted its holdings in OrthoPediatrics by 95.0% in the 2nd quarter. Squarepoint Ops LLC now owns 195,468 shares of the company’s stock worth $3,739,000 after buying an additional 95,230 shares during the period. Waverly Advisors LLC raised its holdings in OrthoPediatrics by 6.7% during the 2nd quarter. Waverly Advisors LLC now owns 12,366 shares of the company’s stock valued at $237,000 after acquiring an additional 775 shares during the period. California State Teachers Retirement System raised its holdings in OrthoPediatrics by 397.1% during the 2nd quarter. California State Teachers Retirement System now owns 4,553 shares of the company’s stock valued at $87,000 after acquiring an additional 3,637 shares during the period. Nantahala Capital Management LLC purchased a new stake in shares of OrthoPediatrics during the second quarter worth $4,636,002. Finally, Grandeur Peak Global Advisors LLC purchased a new stake in shares of OrthoPediatrics during the second quarter worth $954,000. 69.05% of the stock is currently owned by hedge funds and other institutional investors.
About OrthoPediatrics
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Recommended Stories
- Five stocks we like better than OrthoPediatrics
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
